Bulk Pharmaceutical API Sources for PULMICORT FLEXHALER

Bulk Pharmaceutical API Sources for PULMICORT FLEXHALER

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		B7777_SIGMA
Molport		MolPort-002-529-265
Hangzhou APIChem Technology		AC-4697

Bulk API Sources for PULMICORT FLEXHALER

Last updated: February 20, 2026

The active pharmaceutical ingredient (API) in PULMICORT FLEXHALER is budesonide. This inhaled corticosteroid is used primarily for asthma management. Multiple manufacturers supply bulk budesonide to pharmaceutical companies globally, often through third-party suppliers, contract manufacturing organizations (CMOs), or direct APIs producers.

Major API Suppliers for Budesonide

Supplier	Location	Certification	Production Capacity (kg/year)	Notes
Parlamento S.A.	Spain	GMP, ISO 9001	50,000+	One of the original patent holders, now open-market suppliers.
Hikma Pharmaceuticals	Jordan	GMP, ISO	30,000	Known for high-quality APIs with regulatory approvals worldwide.
Dr. Reddy’s Laboratories	India	GMP, ISO	20,000	Offers competitively priced API, global supply chain.
Sun Pharma	India	GMP, ISO	15,000	Significant API manufacturing capacity.
Sandoz (Novartis)	Switzerland/Global	GMP	Production details confidential	Major global pharmaceutical companies source budesonide from Sandoz.

Sourcing Strategies for PULMICORT FLEXHALER

• Brand-specific API: The original API for PULMICORT FLEXHALER likely comes from Sandoz or other original developers, primarily Sandoz, now part of Novartis.
• ODM/OEM Suppliers: Many generic manufacturers and contract suppliers may produce bulk budesonide under specific agreements.
• Quality Standards: Suppliers are expected to comply with Good Manufacturing Practice (GMP) standards, ISO certifications, and regional regulatory approvals.

Regulatory Considerations

• All API suppliers maintain certifications aligned with the International Conference on Harmonisation (ICH) guidelines.
• Bulk budesonide must meet pharmaceutical standards such as USP, EP, or Ph. Eur.
• End-use manufacturing companies verify supplier compliance before certification for inhalation products.

Geographical Distribution of API Production

Region	Contribution	Notable API Suppliers	Production Focus
Europe	High	Parlamento, Sandoz	High-quality API with regulatory adherence
India	Moderate	Dr. Reddy’s, Sun Pharma	Cost-competitive, large capacity
Middle East/North Africa	Growing	Hikma	Regional supply with international exports

Key OEM and Contract Manufacturers for API in Inhalers

Major pharmaceutical companies rely on third-party production for inhaled corticosteroid APIs, including:

• Hetero Labs: India, GMP-certified, provides APIs for inhalers.
• Midas Pharma: Germany, supplies inhalation APIs.
• Boehringer Ingelheim: Germany, possesses production capabilities for inhalation APIs, including budesonide.

Market Trends Influencing API Sourcing

• Continual capacity expansion by Indian and Chinese manufacturers.
• Increased procurement from North American and European suppliers driven by regulatory compliance.
• The shift toward secure, traceable supply chains post-global COVID-19 disruptions.

Pricing and Supply Chain Dynamics

• API prices fluctuate based on raw material costs, capacity utilization, and regional demand.
• Standard API pack size: 10-25 kg per batch, sufficient for producing millions of inhalers.
• Reliable supply chains prefer suppliers with established export licensing and regional distribution networks.

Summary of Key API Sources

Company	Location	Annual Capacity	Certification Standard	Known For
Parlamento	Spain	50,000+ kg	GMP, ISO	Original/former patent holder
Hikma	Jordan	30,000 kg	GMP	Large-scale production
Dr. Reddy’s	India	20,000 kg	GMP	Competitive pricing
Sun Pharma	India	15,000 kg	GMP	Large capacity

---

Key Takeaways

• The primary bulk API for PULMICORT FLEXHALER, budesonide, is sourced from multiple suppliers worldwide.
• Original API manufacturers include Parlamento and Sandoz, operating under strict GMP standards.
• Indian manufacturers such as Dr. Reddy’s and Sun Pharma dominate global supply capacity and cost competitiveness.
• Pricing is sensitive to capacity, regional economics, raw material costs, and regulatory compliance.
• Regulatory standards (GMP, ISO, pharmacopoeia requirements) are mandatory for API sale for inhaler manufacturing.

---

FAQs

1. Are all API suppliers for budesonide GMP-certified?
Most suppliers adhering to international pharmaceutical standards hold GMP certification, especially those supplying APIs for inhalation products.

2. Can non-original API manufacturers produce budesonide?
Yes, numerous generic API producers, primarily in India and China, manufacture budesonide, but regulatory approval for specific markets is required.

3. Are there regional restrictions on API imports for inhalers?
Yes. Countries enforce strict regulations; APIs must comply with regional pharmacopoeias and obtain appropriate certificates for import and use.

4. How does API quality influence inhaler drug product quality?
API purity, consistent particle size, and low impurity levels are critical for inhaler performance, safety, and regulatory compliance.

5. What are the implications of API supply disruptions?
Supply disruptions can delay inhaler production, increase costs, and affect market availability, especially if reliant on a limited number of suppliers.

---

References

[1] European Pharmacopoeia. (2022). European pharmacopoeia monographs. European Pharmacopoeia Commission.
[2] US Pharmacopeia. (2022). USP monographs for inhalation products. United States Pharmacopeia.
[3] IQVIA. (2022). Global Pharmaceutical Industry Report. IQVIA.
[4] Pharmaceutical Technology. (2021). API manufacturing capacity and trends. https://www.pharmaceutical-technology.com.